search
Back to results

Dietary Polyphenols and Glycation in Renal Insufficiency (PoGlyDRI)

Primary Purpose

Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic

Status
Terminated
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Chlorogenic Acid (CGA) enriched coffee
Conventional coffee
Sponsored by
NHS Greater Glasgow and Clyde
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Dietary polyphenols, Protein glycation

Eligibility Criteria

40 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • type 2 Diabetes Mellitus
  • chronic renal insufficiency with persistent eGFR of 35-60mL/min for at least three months
  • fluent in English

Exclusion Criteria:

  • dialysis therapy (current or previous)
  • malignancy
  • transplant recipient
  • hyperthyroidism
  • hypothyroidism
  • high dose glucocorticoids (≥250 mg)
  • body mass index (BMI) ≥ 45 kg/m2
  • special dietary requirements
  • take creatine, antioxidants or vitamin supplements
  • smoker
  • pregnant
  • consume >4 cups of tea/coffee per day
  • consume >5 portion of fruits and vegetables per day

Sites / Locations

  • NHS Greater Glasgow and Clyde
  • University of Glasgow

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Treatment group

Control group

Arm Description

Chlorogenic Acid (CGA) 400mg/day (CGA-enriched coffee)

Conventional coffee (habitual diet)

Outcomes

Primary Outcome Measures

Change in glycohaemoglobin (HbA1c)
Change in estimated glomerular filtration rate (eGFR)

Secondary Outcome Measures

Change in fasting glucose
Change in fructosamine
Change in advanced glycation end product (AGE)
Change in soluble receptor for AGE (sRAGE)
Change in F2-isoprostane
Change in malondialdehyde (MDA)
Change in Urinary Albumin Excretion
Change in creatinine
Change in blood pressure
Change in crystatin C
Change in fibrinogen
Change in cholesterol
Change in C-reactive protein
Change in Interleukin-6
Change in thiobarbituric acid reactive substances (TBARS)
Change in advanced oxidation protein products (AOPP)
Change in 8hydroxy 2'deoxyguanoside (8OhdG)

Full Information

First Posted
July 14, 2015
Last Updated
February 8, 2023
Sponsor
NHS Greater Glasgow and Clyde
Collaborators
University of Glasgow
search

1. Study Identification

Unique Protocol Identification Number
NCT02524938
Brief Title
Dietary Polyphenols and Glycation in Renal Insufficiency
Acronym
PoGlyDRI
Official Title
PoGlyDRI - Impact of Dietary Polyphenols on Protein Glycation in Type 2 Diabetes Mellitus Subjects With Chronic Renal Insufficiency
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Terminated
Why Stopped
Failure to recruit due to human resourcing
Study Start Date
June 1, 2016 (Actual)
Primary Completion Date
September 2022 (Actual)
Study Completion Date
September 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NHS Greater Glasgow and Clyde
Collaborators
University of Glasgow

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Type 2 diabetes mellitus (T2DM) is associated with an increased risk of kidney failure, with high levels of glycohaemoglobin (HbA1c) presenting a sharper decline in renal function and an increase in the risk of mortality and end-stage renal disease (ESRD). Polyphenols may improve renal insufficiency in patients with diabetes with chlorogenic acids (CGA) one of the principle polyphenol groups in the diet - coffee/tea, stone fruits (especially plums/prunes) and some vegetables (artichoke, chicory). CGA (3-4 cups of coffee) has been associated with 25% lower risk of T2DM and a favourable reduction of HbA1c, blood pressure, and oxidative stress levels. This randomised controlled trial, therefore, aims to evaluate the effect of high CGA food on glycation and oxidative stress in T2DM subjects with early renal insufficiency (glomerular filtration rate of 35-60 mL/min) as well as progression of renal insufficiency and the risk of cardiovascular diseases. The study will have two phases - phase I, an interventional study of 3 months followed by phase II, an observational study of 21 months. In phase I, subjects will be randomized into 2 groups: CGA-enriched diet group, or control (habitual) diet group. The treatment group will be provided with a chlorogenic acid-rich food (coffee) with instructions to achieve an intake of 400 mg per day (equivalent to 3-4 coffee cups per day) for 12 weeks. The control group will receive a conventional coffee low in chlorogenic acid. Participants will attend three sessions during phase I; baseline, 6 weeks, and 12 weeks. At baseline, general information, medical history, dietary habits and medication use will be recorded and a Food Frequency Questionnaire completed. Urine and blood samples will be collected and blood pressure, waist circumference, height and weight recorded. Participants' diet over the previous 3 days will be assessed by estimated food diary analysis. In phase II, written dietary recommendations will be provided at three time points (months 6, 12 and 24) - treatment group to achieve a CGA-rich diet (total polyphenol intake of at least 1g per day, and at least 400mg per day of CGA) and standard dietary advice for the control group. Anthropometric/dietary data will be collected as well as blood and urine samples to assess markers of renal function, glycation and oxidative stress, and proteomic markers of cardiovascular disease, coronary artery disease and diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Keywords
Dietary polyphenols, Protein glycation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
9 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment group
Arm Type
Experimental
Arm Description
Chlorogenic Acid (CGA) 400mg/day (CGA-enriched coffee)
Arm Title
Control group
Arm Type
Sham Comparator
Arm Description
Conventional coffee (habitual diet)
Intervention Type
Dietary Supplement
Intervention Name(s)
Chlorogenic Acid (CGA) enriched coffee
Other Intervention Name(s)
CGA-enriched diet
Intervention Description
Chlorogenic Acid (CGA) enriched coffee Phase I: CGA-enriched coffee provided with a CGA content of 70-90 mg/100g. Daily CGA intake of 400mg. Phase II: recommendation for achieving a CGA-rich diet of at least 400mg/day (total polyphenol intake of at least 1g/day)
Intervention Type
Dietary Supplement
Intervention Name(s)
Conventional coffee
Other Intervention Name(s)
Habitual diet
Intervention Description
Phase I: conventional coffee provided (low in CGA) Phase II: standard dietary advice
Primary Outcome Measure Information:
Title
Change in glycohaemoglobin (HbA1c)
Time Frame
3 months
Title
Change in estimated glomerular filtration rate (eGFR)
Time Frame
21 months
Secondary Outcome Measure Information:
Title
Change in fasting glucose
Time Frame
3 months
Title
Change in fructosamine
Time Frame
3 months
Title
Change in advanced glycation end product (AGE)
Time Frame
3 months
Title
Change in soluble receptor for AGE (sRAGE)
Time Frame
3 months
Title
Change in F2-isoprostane
Time Frame
3 months
Title
Change in malondialdehyde (MDA)
Time Frame
3 months
Title
Change in Urinary Albumin Excretion
Time Frame
21 months
Title
Change in creatinine
Time Frame
21 months
Title
Change in blood pressure
Time Frame
21 months
Title
Change in crystatin C
Time Frame
21 months
Title
Change in fibrinogen
Time Frame
21 months
Title
Change in cholesterol
Time Frame
21 months
Title
Change in C-reactive protein
Time Frame
21 months
Title
Change in Interleukin-6
Time Frame
21 months
Title
Change in thiobarbituric acid reactive substances (TBARS)
Time Frame
21 months
Title
Change in advanced oxidation protein products (AOPP)
Time Frame
21 months
Title
Change in 8hydroxy 2'deoxyguanoside (8OhdG)
Time Frame
21 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: type 2 Diabetes Mellitus chronic renal insufficiency with persistent eGFR of 35-60mL/min for at least three months fluent in English Exclusion Criteria: dialysis therapy (current or previous) malignancy transplant recipient hyperthyroidism hypothyroidism high dose glucocorticoids (≥250 mg) body mass index (BMI) ≥ 45 kg/m2 special dietary requirements take creatine, antioxidants or vitamin supplements smoker pregnant consume >4 cups of tea/coffee per day consume >5 portion of fruits and vegetables per day
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Emilie Combet, PhD
Organizational Affiliation
University of Glasgow
Official's Role
Principal Investigator
Facility Information:
Facility Name
NHS Greater Glasgow and Clyde
City
Glasgow
Country
United Kingdom
Facility Name
University of Glasgow
City
Glasgow
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Dietary Polyphenols and Glycation in Renal Insufficiency

We'll reach out to this number within 24 hrs